Inactive Instrument

Theseus Pharmaceuticals, Inc.

THRX

US88369M1018

Biotechnology & Medical Research

Theseus Pharmaceuticals, Inc. Announces Employment Termination of Timothy P. Clackson as Chief Executive Officer, Effective December 7, 2023

December 04, 2023 at 06:31 am EST

Theseus Pharmaceuticals, Inc. terminated the employment of Timothy P. Clackson, Ph.D. as Chief Executive Officer of the Company, effective as of December 7, 2023, without cause.

Latest news about Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc. Announces Board Resignations	Feb. 14	CI
Theseus Pharmaceuticals, Inc.(NasdaqGS:THRX) dropped from NASDAQ Composite Index	Feb. 13	CI
Concentra Biosciences, LLC completed the acquisition of Theseus Pharmaceuticals, Inc..	Feb. 13	CI
Theseus Pharmaceuticals, Inc.(NasdaqGS:THRX) dropped from S&P TMI Index	Feb. 08	CI
Sector Update: Health Care Stocks Gain in Late Afternoon	Dec. 22	MT
Sector Update: Health Care Stocks Higher Friday Afternoon	Dec. 22	MT
Sector Update: Health Care Stocks Mixed Premarket Friday	Dec. 22	MT
Theseus Pharmaceuticals to be Acquired by Concentra Biosciences; Shares Rise Pre-Bell	Dec. 22	MT
Theseus Pharmaceuticals, Inc. Announces Employment Termination of Timothy P. Clackson as Chief Executive Officer, Effective December 7, 2023	Dec. 04	CI
Theseus Pharmaceuticals, Inc. Announces Management Changes	Dec. 04	CI
Theseus Pharmaceuticals Receives Acquisition Offers From Foresite, OrbiMed, Concentra Biosciences	Nov. 27	MT
Concentra Biosciences, LLC sent an unsolicited proposal to acquire Theseus Pharmaceuticals, Inc..	Nov. 26	CI
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading	Nov. 22	DJ
Theseus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Sector Update: Health Care Stocks Higher Late Afternoon	Nov. 14	MT
Sector Update: Health Care	Nov. 14	MT
Top Midday Gainers	Nov. 14	MT
Top Premarket Gainers	Nov. 14	MT
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives	Nov. 12	CI
North American Morning Briefing : Stock Futures -2-	Nov. 08	DJ
Theseus Pharmaceuticals, Inc. Provides Written Notice to ARIAD Pharmaceuticals, Inc. of its Termination of the License Agreement	23-10-31	CI
Theseus Pharmaceuticals, Inc.(NasdaqGS:THRX) dropped from S&P Global BMI Index	23-09-18	CI
Theseus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Insider Buy: Theseus Pharmaceuticals	23-07-19	MT

Chart Theseus Pharmaceuticals, Inc.

Duration

Period

More charts

Theseus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on treating cancer patients through the discovery, development, and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. It also focused on tyrosine kinase inhibitors (TKIs), which is rooted in the critical role that tyrosine kinases play in the development of cancer. It develops pan-variant kinase inhibitors-inhibitors that target cancer-causing and drug resistance mutations in clinically protein kinases. Its product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase for the treatment of GIST, a type of cancer often characterized by oncogenic activation of KIT. It is also developing THE-349, a selective epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.61%	102B
REGENERON PHARMACEUTICALS, INC.	+2.29%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-16.97%	21.4B
GENMAB A/S	-8.79%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-13.90%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+6.65%	13.83B
SAREPTA THERAPEUTICS, INC.	+32.05%	11.97B

Bio Therapeutic Drugs